Remove 2023 Remove FDA Remove Healthcare Provider Remove Side effects
article thumbnail

Healthcare Watch October 2023

PM360

Of the eight FDA-approved weight loss drugs on the market, these two are making waves for doctors who believe they represent “a new era for weight loss medications,” and “changing options and giving hope.” “They are effective but too expensive for the majority of patients, even with insurance coverage,” said one primary care physician (PCP).

article thumbnail

Almirall/Lilly lebrikizumab offers potential long-term management of atopic dermatitis

pharmaphorum

Minor side effects to long-term maintenance balance. Any clinical study seeks to achieve maximum results efficacy with minimal occurrence of side effects. However, side effects do happen. Regarding both common cold and headache, they are as well among the side effects reported for similar drugs.

article thumbnail

The State of the Union in Cancer Innovation

PM360

The FDA has granted Fast Track Designation for our HER2-targeted ADC, ARX788, and we are enrolling the signal-seeking ACE-Breast-03 Phase 2 clinical study in post-Enhertu mBC patients throughout 2H 2023. Preliminary data are expected in 2023. What Other Developments Within Oncology Excite You?